Biomarkers are the heart of disease diagnostics. A biomarker, or biological marker, refers to something that can be measured to reliably and accurately indicate the presence and severity of a disease or condition. Biomarkers include a wide array of measurable indicators ranging anywhere from an elevated white blood cell count to indicate infection to the presence of beta-amyloid plaques in the brain to indicate Alzheimer’s disease.
With the rise of digital health data collection, researchers and providers alike are embracing the potential of digital biomarkers. The newer concept of digital biomarkers, as the name suggests, refers to the idea of collecting clinically meaningful data through digital devices. Digital biomarkers may provide a new, more robust method for monitoring and diagnosing neurological diseases and other conditions, and they enable the collection and analysis of physiological and behavioral data which may be used for predictive diagnosis of diseases, such as Alzheimer’s.
Digital biomarkers for Alzheimer’s disease may facilitate early diagnosis as well as the ability for Alzheimer’s patients to gain access to treatments and therapies earlier on when the disease is more treatable, providing better health outcomes. Let’s take a deeper look into digital biomarkers, their significance, and the future of Alzheimer’s disease diagnosis.
Digital biomarkers are quantifiable, objective physiological and behavioral data that are collected and measured via a digital device. Such devices include portables, wearables, implantables, or digestibles. Digital biomarkers yield new and robust data sets that can be used to learn more about the nuances of specific diseases and gain valuable health insight.
Passive data from sensors integrated into wearable devices, such as smartwatches, is generated when a user simply wears the device. The data collected is then referred to as passive digital biomarker data. Similarly, digital biomarker data can be generated and captured from smart devices, such as smartphones and tablets, when a user interacts with the device in response to an active prompt. Integrated sensors including cameras, microphones, touchscreen sensors, accelerometers, and gyroscopes can be used to collect active digital biomarker data.
While wearables collect more obvious data—such as heart rate, heart rate variability, and oxygen saturation levels from photoplethysmography sensors—smartphones and tablets collect less intuitive, yet incredibly powerful data. Here are some examples of digital biomarker data that can be collected from smart devices:
As more and more individuals embrace newer health-related technologies, the amount of available health data is growing at a staggering rate. When this volume of data is paired with strong analytical tools, it can potentially be leveraged to track trends and patterns for many diseases, including Alzheimer’s disease. Artificial intelligence can be used to detect such patterns and build models that weigh large data sets of digital biomarkers to identify the presence of neurological disease. Digital biomarkers for Alzheimer’s disease may enable early diagnosis and consequently, early intervention. At their core, digital biomarkers offer significant value toward better monitoring and diagnostic tools for Alzheimer’s disease.
The potential to use digital biomarkers for Alzheimer’s disease to enable early diagnosis lies in the ability to determine which biomarkers are clinically significant as well as finding a powerful method to analyze large quantities of data.
Altoida is developing a precision neurology platform that will measure and analyze a wide range of both cognitive and functional digital biomarkers associated with cognitive impairment, providing a comprehensive analysis of neurocognitive function on a personalized level. Using smart devices, users will complete a 10-minute set of activities that are designed to place the user’s brain under a higher cognitive load while mimicking aspects of day-to-day activities.
Our unique method for collecting and analyzing nearly 800 active digital biomarkers will enable highly specific, accurate, and generalizable data for both cross-sectional and longitudinal analysis of brain health. This method, along with our innovative artificial intelligence, will serve as the infrastructure for our work towards predictive diagnostics.
To learn more about Altoida’s digital platform—or how digital biomarkers for Alzheimer’s disease will enable early diagnosis—contact us today.